What began with the introduction of Semaglutyd has now evolved into a broader spectrum of medications targeting obesity more efficiently than ever before. The journey from the early days of GLP-1 receptor agonists to the latest entrant, Retatrutyd, marks a pivotal moment in the medical weight loss industry. https://tirzefit.blogocial.com/from-sema-to-retatrutide-2025-s-top-fat-drugs-70782553